One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice;Évolution métabolique après un an de patients diabétiques de type 2 traités par exénatide et suivis en routine clinique

Diabetes and Metabolism

Volumn 36, Issue 5, 2010, Pages 381-388

  Buysschaert, M ^a   Preumont, V ^a   Oriot, P R ^a   Paris, I ^a   Ponchon, M ^a   Scarniere D ^a   Selvais, P ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Efficacy; Exenatide; HbA1c; Routine practice; Side effects; Weight

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BODY WEIGHT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SEX DIFFERENCE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GASTROINTESTINAL DISEASES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VENOMS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 78649447003     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.03.009     Document Type: Article

References (33)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
2. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. The ADVANCE Collaborative Group.
3. Ray K.K., Seshasai S.R.K., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized-controlled trials. Lancet 2009, 373:1765-1772.
4. Gæde P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
5. Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(suppl. 1):S11-S61. American Diabetes Association.
6. Liebl A., Mata M., Eschwege E. Evaluation of risk factors for development of complications in type 2 diabetes in Europe. Diabetologia 2002, 45:S23-S28.
7. Saydah S.H., Fradkin J., Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004, 291:335-342.
8. Buysschaert M., Hermans M.P. The treated-to-target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients. Acta Clinica Belgica 2005, 60-2:79-85.
9. Eliasson B., Eeg-Olofsson K., Cederholm J., Nilsson P.M., Gudbjönsdottir S. For the Steering Committee of the Swedish National Diabetes Register (NDR). Diabetes Metab 2007, 33:269-276.
10. Hoeger T.J., Segel J.E., Gregg E.W., Saaddine J.B. Is glycemic control improving in US adults. Diabetes Care 2008, 31:81-86.
11. Kunt T., Snoek F.J. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract 2009, 63:6-10.
12. Calvert M.J., McManus R.J., Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007, 57:455-460.
13. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26(Suppl. 3):S18-S24.
14. Polonsky W.H., Fisher L., Guzman S., Villa-Caballero L., Edelman S.V. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005, 28:2543-2545.
15. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabetes Care 2005, 28:2673-2679.
16. De Fronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
17. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (Exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
18. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
19. Riddle M.C., Henry R.R., Poon T.H., Zhang B., Mac S.M., Holcombe J.H., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulfonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22:483-491.
20. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
21. Barnett A.H., Burger J., Johns D., Brodows R., Kendall D.M., Roberts A., et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, cross-over noninferiority trial. Clin Ther 2007, 29:2333-2348.
22. Nauck M.A., Duran S., Kim D., Johns D., Northrup J., Festa A., et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a noninferiority study. Diabetologia 2007, 50:259-267.
23. Bunck M.C., Diamant M., Cornér A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves ß-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. A randomized-controlled trial. Diabetes Care 2009, 32:762-768.
24. Klonoff D.C., Buse J.B., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res 2008, 24:275-286.
25. 1c and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009, 11:1122-1130.
26. De Block C., Paquot N., Daoudi N., Ballaux D., Van Gaal L.F., Scheen A.J. Amélioration du contrôle glycémique et perte de poids sous exénatide chez des patients diabétiques de type 2: résultats d'une étude rétrospective observationnelle multicentrique belge. Rev Med Liege 2009, 64:488-495.
27. Expert Committee on the diagnosis and classification of diabetes mellitus: report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20:1183-97.
28. Buysschaert M., Claessens A., Damoiseaux P., Derdelinckx L., Dramais A.S., Duvivier E., et al. Effets à court et moyen terme d'un traitement par exénatide dans une cohorte de diabétiques de type 2 ; résultats d'une étude multicentrique. Louvain Med 2010, 129:49-53.
29. Buse J.B., Klonoff D.C., Nielsen L.L., Guan X., Bowlus C.L., Holcombe J.H., et al. Metabolic effects of 2years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double blind, placebo-controlled trials. Clin Ther 2007, 29:139-153.
30. Lienart D., Preumont V., Alexopoulou O., Donckier J., Colson A., Hermans M.P., et al. Metabolic (glycaemic, lipidic) and blood pressure control in 101 type 2 diabetic patients on first admission to diabetes centres. Acta Clinica Belgica 2006, 61:127-133.
31. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R., Sherwing R., et al. Medical management of hyperglycemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009, 52:17-30.
32. Preumont V., Hermans M., Brichard S., Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab 2010, 36. [accepted for publication].
33. Adler A., Shaw E.J., Stokes T., Ruiz Fr. On behalf of the guideline development group newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 2009, 338:1328-1331.